Based on the literature data, we decided to also include the Wilms Tumor Protein (WT1), which was described as a mediator of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) resistance in AML by regulating BCL2L1 [56]. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.